so with such insights what do you @Teddyward say to this report...

First 22 Last

Share
Profile

Follow
Maz2024

48 Posts.

4

27/03/24

21:55

Post #: 73092604
Share

Originally posted by Teddyward: ↑

Ya see I wouldn't know as there was no graphs or numbers offered in the announcement. General shallow company comments that are not specific regarding " will support" doesn't in any way mean they will fully support or meet requirements for even current claims let alone extended ones.

SPL may just be struck by a rainbow that original timelines in regards to post market studies were amended .........

Does make me wonder why we have trials at all and set levels of statistical significance if any old number will do?
Meaningful - Well meaningful would be seeing the graphs missing along with a formal explanation of the non compliance in various age groups etc etc But hey why restrict the very information that would help shareholders see a meaningful result. Hmmm guess they want to keep that meaningful surprise for presenting at world conferences explaining why statistical significance is no longer the hurdle for trials ?

Expand

so with such insights what do you @Teddyward say to this report https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting
and how come doctors are prescribing to the vacinated with p=0.49. Is that statistically significant.. ❓ and TGA only remember has temporary approval on Paxlovid

SPL Price at posting: 13.0¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 8 more messages in this thread...

First 22 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.00M

Open	High	Low	Value	Volume
9.8¢	10.5¢	9.6¢	$210.8K	2.098M

Buyers (Bids)

No.	Vol.	Price($)
1	30408	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.7¢	3523	2

View Market Depth

No.	Vol.	Price($)
1	30408	0.095
2	15638	0.094
3	83394	0.093
2	108435	0.091
2	41000	0.090

Price($)	Vol.	No.
0.097	3523	2
0.105	119848	4
0.110	114099	6
0.115	77331	6
0.120	89055	5

Last trade - 16.10pm 09/07/2024 (20 minute delay)

SPL (ASX) Chart

so with such insights what do you @Teddyward say to this report...

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

so with such insights what do you @Teddyward say to this report...

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News